Page 3 - சந்தேற மருந்துகள் வைத்திருத்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Santhera Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber s Hereditary Optic Neuropathy
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Santhera Pharmaceuticals Holding AG: Santhera s Phase-4-Studie LEROS mit Raxone bei Leber hereditärer Optikusneuropathie erreicht primären Endpunkt
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Santhera Pharmaceuticals Holding AG: Santhera Publishes Agenda for its Annual General Meeting
the invitation to its Annual General Meeting (AGM)
, at 10:30
.
Invitation and agenda items for the AGM
The invitation and agenda items for the Annual General Meeting can be viewed on Santhera s website at https://www.santhera.com/investors-and-media/investor-toolbox/share-bondholder-meetings.
Selected agenda items:
increases
As previously announced, the Board of Directors (BoD) proposes various capital increases to Santhera s shareholders at the forthcoming AGM. These should give the Company sufficient flexibility to raise additional capital to fund ongoing development activities, increase pre-commercialization activities and expand the organization in view of a US market launch of vamorolone in late 2022, subject to positive results of the pivotal VISION-DMD study. Specifically, the BoD proposes:
is starting today on the SIX Swiss Exchange.
On May 4, 2021, Santhera Pharmaceuticals Holding AG issued Senior Unsecured Convertible Bonds due 2024 (the
2021/24 Bonds) in the aggregate principal amount of CHF 30,270,375. The 2021/24 Bonds have been admitted to trading on the SIX Swiss Exchange. The first trading day is today, May 7, 2021. The ticker symbol of the 2021/24 Bonds is SAN21 and ISIN CH0563348744.
As set out in the terms and conditions [1], the conversion period during which a bondholder may exercise the conversion rights for the 2021/24 Bonds has started on May 4, 2021, and ends seven trading days before the maturity date on August 17, 2024 (or, in case of early redemption, ten trading days prior to the date fixed for early redemption).